Predictive factors of poor prognosis in cancer patients with chemotherapy-induced febrile neutropenia
- 16 June 2010
- journal article
- research article
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 19 (8) , 1151-1158
Abstract
We intended to determine the predictive factors of poor prognosis in cancer patients with chemotherapy-induced febrile neutropenia (FN). From January 1, 2007 to December 31, 2008, 396 episodes of FN in 346 cancer patients were retrospectively analyzed. Clinical and laboratory findings and Multinational Association of Supportive Care in Cancer (MASCC) risk-index score were analyzed and correlated with outcome. Of the 396 episodes, 73 (18.4%) had serious medical complications including 15 (3.8%) deaths. There was significant difference between unfavorable and favorable outcomes in age, gender, hypotension, tachypnea, duration of fever ≤24 h before admission (44.4% vs. 61.3%), interval of ≤7 days since last chemotherapy (34.2% vs. 16.1%), and duration of neutropenia ≥4 days (34.2% vs. 15.8%; P < 0.05 each), as did C-reactive protein (CRP; 15.0 vs. 7.5 mg dL-1) and platelet count (66.4 × 103 vs. 123.7 × 103 mm-3;P < 0.001 each). MASCC score was significantly lower in unfavorable outcomes than favorable outcomes (19.0 vs. 24.6, P < 0.001). However, prophylactic antibiotics, treatment with granulocyte colony-stimulating factor (G-CSF), and history of FN were not associated with outcome. On multivariate analysis, MASCC risk-index score (OR 23.2, 95% CI 10.48–51.37), tachypnea (OR 3.61, 95% CI 1.44–9.08), thrombocytopenia (OR 3.41, 95% CI 1.69–6.89), increased CRP (OR 3.23, 95% CI 1.62–6.45), and prolonged neutropenia (OR 2.52, 95% CI 1.21–5.25) were independent predictors of unfavorable outcomes. MASCC risk-index score <21, tachypnea, thrombocytopenia, increased CRP, and prolonged neutropenia may be strongly associated with poor outcomes in cancer patients with FN.Keywords
This publication has 32 references indexed in Scilit:
- Severe sepsis in autologous stem cell transplant recipients: Microbiological aetiology, risk factors and outcomeScandinavian Journal of Infectious Diseases, 2009
- Performance of Interleukin-6 and Interleukin-8 serum levels in pediatric oncology patients with neutropenia and fever for the assessment of low-riskBMC Infectious Diseases, 2008
- Prediction of outcome in cancer patients with febrile neutropenia: comparison of the Multinational Association of Supportive Care in Cancer risk-index score with procalcitonin, C-reactive protein, serum amyloid A, and interleukins-1β, -6, -8 and -10European Journal of Cancer Care, 2007
- Management of febrile neutropenia in solid tumours and lymphomas using the Multinational Association for Supportive Care in Cancer (MASCC) risk index: feasibility and safety in routine clinical practiceSupportive Care in Cancer, 2007
- Change of procalcitonin predicts clinical outcome of febrile episodes in patients with hematological malignanciesSupportive Care in Cancer, 2006
- Fluoroquinolone resistance of Escherichia coli at a cancer center: epidemiologic evolution and effects of discontinuing prophylactic fluoroquinolone use in neutropenic patients with leukemiaEuropean Journal of Clinical Microbiology & Infectious Diseases, 2005
- An evidence-based evaluation of important aspects of empirical antibiotic therapy in febrile neutropenic patientsClinical Microbiology and Infection, 2005
- Monotherapy versus Dual Therapy Based on Risk Categorization of Febrile Neutropenic PatientsClinical Infectious Diseases, 2004
- Febrile neutropenia: a prospective study to validate the Multinational Association of Supportive Care of Cancer (MASCC) risk-index scoreSupportive Care in Cancer, 2004
- C-Reactive Protein and Fever in Neutropenic PatientsScandinavian Journal of Infectious Diseases, 2000